|
PDC (≥ 80% vs. <50%)
|
0.81
|
(0.515, 1.231)
|
0.48
|
|
PDC (≥ 50% ≤80% vs. < 50%)
|
0.91
|
(0.479, 1.741)
|
0.94
|
|
Age
|
1.00
|
(0.976, 1.016)
|
0.66
|
|
Gender (Female vs. Male)
|
1.37
|
(0.796, 2.368)
|
0.25
|
|
Race (Black vs. White)
|
1.41
|
(0.558, 3.538)
|
0.48
|
|
Race (Hispanic vs. White)
|
0.42
|
(0.048, 3.599)
|
0.29
|
|
Race (Other vs. White)
|
1.80
|
(0.689, 4.703)
|
0.22
|
|
Fracture in 6 Month Period before Initiating Teriparatide
|
2.93
|
(2.084, 4.122)
|
<.0001
|
|
Charlson Comorbidity
|
0.96
|
(0.861, 1.07)
|
0.46
|
|
Geographic Region (West vs. Northeast)
|
1.38
|
(0.347, 5.513)
|
0.99
|
|
Geographic Region (Southeast vs. Northeast)
|
2.07
|
(0.566, 7.531)
|
0.05
|
|
Geographic Region (Midwest vs. Northeast)
|
1.29
|
(0.341, 4.889)
|
0.76
|
|
Bisphosphonate Use
|
1.04
|
(0.738, 1.469)
|
0.82
|
|
Calcitonin Use
|
0.62
|
(0.283, 1.378)
|
0.24
|
|
Selective Estrogen Receptor Modulator Use
|
1.16
|
(0.551, 2.433)
|
0.70
|
|
Estrogen Use
|
0.61
|
(0.197, 1.891)
|
0.39
|
